Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome

We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with per...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Bixin, Zhou, Chen, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142797/
https://www.ncbi.nlm.nih.gov/pubmed/34084507
http://dx.doi.org/10.1002/ccr3.4111
Descripción
Sumario:We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with personalized low‐dose chemotherapy and subsequently remained in complete remission for 1 year.

Ejemplares similares